Glutathione-S-transferase T1 (GSTT1) and GSTM1 detoxify carcinogens and thus potentially contribute to inter-individual susceptibility to cancer. We determined the ability of GST copy number variation (CNV) to predict the risk of cancer in the general population. Exact copy numbers of GSTT1 and GSTM1 were measured by real-time PCR in 10 247 individuals, of whom 2090 had cancer. In men, the cumulative incidence of prostate cancer increased and the cumulative 5-year survival decreased with decreasing GSTT1 copy numbers (trends ¼ 0.02). The hazard ratios (HRs) (95% CIs) for prostate cancer and for death after prostate cancer diagnosis were, respectively, 1.2 (0.8-1.8) and 1.2 (0.6-2.1) for GSTT1*1/0, and 1.8 (1.1-3.0) and 2.2 (1.1-4.4) for GSTT1*0/0 versus GSTT1*1/1. In women, the cumulative incidence of corpus uteri cancer increased with decreasing GSTT1 copy numbers (trend ¼ 0.04). The HRs for corpus uteri cancer were, respectively, 1.8 (1.0-3.2) and 2.2 (1.0-4.6) for GSTT1*1/0 and GSTT1*0/0 versus GSTT1*1/1. Finally, the cumulative incidence of bladder cancer increased, and the cumulative 5-year survival decreased, with decreasing GSTM1 copy numbers (P ¼ 0.03-0.05). The HRs for bladder cancer were, respectively, 1.5 (0.7-3.2) and 2.0 (0.9-4.3) for GSTM1*1/0 and GSTM1*0/0 versus GSTM1*1/1. The HR for death after bladder cancer diagnosis was 1.9 (1.0-3.7) for GSTM1*0/0 versus GSTM1*1/0. In conclusion, exact CNV in GSTT1 and GSTM1 predict incidence and 5-year survival from prostate and bladder cancer, and incidence of corpus uteri cancer.
Introduction
Cancer is one of the leading causes of morbidity and mortality in affluent societies. 1 It is generally accepted that cancer risk is influenced by the interaction of environmental and genetic components. Thus, the study of genes encoding proteins involved in the detoxification of environmental carcinogens is of major importance for the determination of inter-individual susceptibility to cancer.
Glutathione-S-transferases (GSTs) are a superfamily of phase-II drug-metabolizing enzymes catalyzing the conjugation of reduced glutathione with a variety of electrophilic compounds, including environmental toxins in smoke, air pollution and industrial chemicals, thereby protecting the cell against xenobiotics and oxidative stress. 2 Two genes from the GST family, GSTM1 and glutathione-S-transferase T1 (GSTT1), show variation in copy number. The null genotypes, GSTM1*0/0 and GSTT1*0/0, are associated with loss of catalytic activity, 3, 4 and a gene dosage effect between gene copy number and enzyme activity has been reported for both the genes. 5, 6 The underlying hypothesis in epidemiological studies is that GST*0/0 individuals are at an increased risk of DNA mutations in susceptible tissues due to lack of protection against carcinogens. Studies of GST genotype in relation to various cancers have shown inconsistent results, [7] [8] [9] with the exception of a consistent association between GSTM1*0/0 and bladder cancer. 7, 10 A potential explanation for these inconsistent results is that the majority of studies fail to determine the exact copy number variation (CNV), and discriminate only between carriers (GST*1/0 þ GST*1/1) and non-carriers (GST*0/0) of the GST genes. To detect gene dosage effects on cancer risk in the general population, we previously developed a highthroughput, real-time PCR method for the determination of the exact gene copy numbers of GSTM1 and GSTT1. 11 We tested the hypothesis that CNV in GSTM1 and GSTT1 predicts the risk of cancer in the general population. For this purpose, the exact gene copy numbers of GSTM1 and GSTT1 were determined in 10 247 Danish participants in the Copenhagen City Heart Study, of whom 2090 had cancer.
Materials and methods

Study population
The Copenhagen City Heart Study (CCHS) is a prospective population study initiated in 1976. Study participants were randomly selected, by sex and within 5-year age strata, from a sample of the approximately 90 000 inhabitants living within 10 wards of Rigshospitalet, Copenhagen University Hospital, using the national Danish Civil Registration System, which reflects the persons date of birth and sex. The study cohort reflected the adult Danish general population aged 20 years or older. 12, 13 All participants were white and of Danish descent. The CCHS was initiated in 1976-1978 with follow-up examinations in 1981-1983, 1991-1994 and 2001-2003 . The first examination included 14 223 individuals (response rate 74%). At the second examination, the original cohort was supplemented with 500 individuals aged 20-24 years (12 698 individuals in total, response rate 70%). At the third examination, the original cohort was supplemented with 3000 individuals aged 20-49 years (10 135 individuals in total, response rate 61%). Finally, at the fourth examination, the original cohort was supplemented with 1040 individuals aged 20-34 years (6238 individuals in total, response rate 50%). Of the 14 223 participants that attended the first examination, 11 135 participants (78%) attended the second examination, 7073 participants (50%) attended the third examination and 3620 participants (25%) attended the fourth examination. At the third and fourth examinations a total of 10 386 participants (99%) gave blood for DNA analysis, of these 10 271 (99%) were successfully genotyped for CNV in both GSTM1 and GSTT1, and 10 247 were included in this study (24 individuals with three gene copies were excluded due to low numbers).
At all four examinations, participants were interviewed regarding alcohol consumption, smoking habits and reproductive history (women only), and had a detailed medical history taken as well as a physical examination. All participants gave written informed consent, and the study was approved by the local ethical committees: Table 2 online. The maximum and median follow-up period was 22 and 28 years, respectively.
For 5-year survival analysis, death endpoints were collected from the Danish Civil Registration System. Only cancers diagnosed after blood sampling, that is, only incident cancers, were included. Follow-up started at cancer diagnosis and ended at death, emigration or 11 August 2007, whichever came first.
Genotyping
Exact copy number determination of GSTM1 and GSTT1 in the entire cohort was performed using high-throughput, real-time PCR as described previously. 11 In brief, the GST gene and the endogenous control, RNAseP, were simultaneously amplified in a 10 ml final volume and copy number was determined using the DC t method. The essential criteria for the quality assurance of the real-time, high-throughput PCR method have been described in detail. 11 As a qualitycontrol method for genotyping, we validated genotypes for 264 samples-40 for each of the genotypes *0/0, *1/0 and *1/ 1 for both genes and all 24 *2/1 samples with three GST copies by the gold standard genotyping method, long-range PCR. There was 100% agreement with genotypes as determined by high-throughput, real-time PCR for the *0/0 and *1/0 genotypes, and as expected, long-range PCR could not discriminate clearly between the *1/1 and *2/1 genotypes and typed both genotypes as *1/1, although the separation of these genotypes was quite clear using real-time PCR. A total of 115 samples (1%) were undetermined for the GSTT1 and/or GSTM1 genotypes after rerun. The undetermined genotypes were samples with atypical amplification plots, samples with no amplification of RNaseP and samples identified as at risk of misclassification by Rankit plots. 17 Both genotypes were in Hardy-Weinberg equilibrium (w 2 -test: P (GSTM1) ¼ 0.32; P (GSTT1) ¼ 0.27). Samples with three GST gene copies (n ¼ 24) were excluded due to the low number, leaving 10 247 participants for all further analyses.
Statistical analysis
The association between GST copy number and risk of cancer was explored in 27 cancer subgroups (Supplementary Table 1 online). All analyses were performed using the statistical software STATA version 10.0 (Stata-Corp, College Station, TX, USA). A P-value o0.05 on a two-sided test was considered significant. The Mann-Whitney U-test was used for continuous variables and Pearson's w 2 -test was used for categorical values.
The cumulative incidence of cancer subtypes and survival after cancer diagnosis, stratified by genotype, was plotted as Kaplan-Meier curves and the log-rank test was applied to test for differences. Hazard ratios (HRs) for cancer and survival after diagnosis of cancer were calculated using Cox regression adjusted for age at entry into the CCHS and age at diagnosis (and sex), respectively. Multifactorially adjusted models included time-dependent covariates from the 1976 to 1978, 1981 to 1983, 1991 to 1994, and 2001 to 2003 examinations. Multifactorial adjustment for prostate cancer included age and body mass index, and for corpus uteri cancer, age, body mass index, parity, current use of oral contraceptives, menopausal status and current use of hormonal replacement therapy. Multifactorial adjustment for bladder cancer included age, sex and smoking status, and for brain cancer it included age and sex. The proportional hazard assumption for Cox regression was tested graphically by plotting -ln(-ln[survival probability]) versus ln(analysis time) for all comparisons; no violations were observed. Twofactor interaction terms between each of the two genotypes and each of the covariates were tested in the Cox regression.
Results
Median age (interquartile range) at study entry was 45 years (36-54) for women and 44 years (35-52) for men. The basic characteristics of the participants at study entry are shown in Table 1 . Individuals with cancer were older, smoked more and had slightly higher body mass index at study entry than individuals without cancer. Women with cancer were more likely to be postmenopausal and to use hormonal replacement therapy at study entry, and less likely to be nulliparous and to use oral contraceptives at entry as compared with women without cancer ( Table 1) .
The genotype distribution for GSTM1 in the general population of 10 247 individuals was 52 *0/0, 40 *1/0 and 8% *1/1. For GSTT1, the genotype distribution was 15 *0/0, 48 *1/0 and 38% *1/1.
The association between GST copy number and risk of cancer was explored in 27 cancer subgroups (Supplementary Table 1 online). Only cancer subgroups where the number of gene copies was significantly associated with risk of cancer (P for trend o0.05) are presented in the following sections.
Risk of cancer subtypes by GSTT1 CNV In men, the cumulative incidence of prostate cancer increased with decreasing GSTT1 copy numbers (Figure 1a, log rank: P for trend ¼ 0.02) and was highest in GSTT1*0/0 individuals (log rank: *0/0 versus *1/1: P ¼ 0.02). At the age of 80 years, about 10 of *0/0, 7 of *1/0 and 5% of *1/1 males had prostate cancer. The multifactorially adjusted HRs (95% confidence interval (CI)) for prostate cancer as obtained from Cox regression were 1.2 (0.8-1.8) for GSTT1*1/0 and 1.8 (1.1-3.0) for GSTT1*0/0 versus GSTT1*1/1 ( Table 2 , P ¼ 0.02). In women, the cumulative incidence of corpus uteri cancer increased with decreasing GSTT1 copy numbers The characteristics in the table represent data at study entry (1976-1978, 1981-1983, 1991-1994 or 2001-2003) for all the 10 247 participants eligible for study. 1 Po0.05.
(Figure 1b, log rank: P for trend ¼ 0.04), and was highest in GSTT1*0/0 individuals (log rank: *0/0 versus *1/1: P ¼ 0.06). At the age of 80 years, about 3 of *0/0, 3 of *1/0 and 1% of *1/1 women had corpus uteri cancer. The multifactorially adjusted HRs (95% CI) for corpus uteri cancer were 1.8 (1.0-3.2) for GSTT1*1/0 and 2.2 (1.0-4.6) for GSTT1*0/0 versus GSTT1*1/1 ( Table 2 , P ¼ 0.03).
Risk of cancer subtypes by GSTM1 CNV The cumulative incidence of bladder cancer increased with decreasing GSTM1 copy numbers (Figure 1c (Figure 2d ). The age-and sex-adjusted HR (95% CI) for death after bladder cancer diagnosis as obtained from Cox regression was 1.9 (1.0-3.7) for GSTM1*0/0 versus GSTM*1/0 (Figure 2d ). There was no association between genotypes and 5-year survival after diagnosis of corpus uteri or brain cancer (data not shown).
Discussion
This is the first study to examine association between exact CNV in the GSTM1 and GSTT1 genes, and risk of cancer in a large study of the general population (n ¼ 10 247). The major findings are that exact CNV in GSTT1 predicts prostate cancer and 5-year survival from prostate cancer in men and corpus uteri cancer in women, whereas CNV in GSTM1 predicts bladder cancer and 5-year survival from bladder cancer in a gene-dose-dependent manner, with GSTnull genotypes (*0/0) having the highest risk.
GST genes and environmental exposure Long-term, low-dose exposure to certain chemicals have been suggested to increase the risk of prostate cancer in the general population, 18 and a recent meta-analysis pointed to pesticide exposure as a possible risk factor for prostate a b c Figure 1 Cumulative incidence of (a) prostate cancer, (b) corpus uteri cancer and (c) bladder cancer as a function of age, and stratified by GST genotype, in the general population. The log-rank test was applied to test for differences. Only cancer types with more than 40 events are shown. GST, glutathione-S-transferase.
cancer. 19 The incidence of prostate cancer has been shown to increase at migration from low-risk (Japan) to high-risk (USA) areas, 20 and the incidence is rapidly increasing in the industrialized countries. These observations suggest that prostate cancer risk is affected by environmental factors. Consequently, protective pathways (for example GST enzymes) may have a relevant role in the pathogenesis of prostate cancer. 8 Besides catalyzing the conjugation of toxins in smoke, air pollution and industrial chemicals, GSTs also detoxify carcinogenic quinone metabolites of estrogens. 21 Both the prostate and the endometrium are estrogen-responsive tissues, and increased estrogen levels predispose to both prostate cancer 22, 23 and corpus uteri cancer. 24 The increasing exposure to estrogens in societies with a Western-type lifestyle, 22 and in particular the contribution from a wide range of xenoestrogens with direct estrogen-like actions (that is, certain herbicides, pesticides, fungicides, plasticizers and polystyrenes), 25 ), parity (number of children; 0 versus 1 versus 2 versus X3), current use of oral contraceptives (yes versus no), menopausal status (yes versus no) and current use of hormone replacement therapy (yes versus no). Follow-up started at study entry (1976-1978, 1981-1983, 1991-1994 or 2001-2003) and ended at the date of the first relevant cancer diagnosis, death, emigration or 31 December 2003, whichever came first. Abbreviations: CI, confidence interval; GSTM1, glutathione-S-transferase M1; HR, hazards ratio. The data for bladder cancer show survival analyses and Cox regression analyses for 10 239 individuals. Eight participants were excluded because of a bladder cancer diagnosis before study entry. The data for brain cancer show survival analyses and Cox regression analyses for 10 245 individuals. Two participants were excluded because of a brain cancer diagnosis before study entry. In the Cox regression model, age is adjusted for by incorporating age in the baseline hazard function (left truncation). Multifactorial adjustment for bladder cancer included age, sex and smoking status (yes versus no); and for brain cancer it included age and sex. Follow-up started at study entry (1976-1978, 1981-1983, 1991-1994 or 2001-2003) and ended at the date of the first relevant cancer diagnosis, death, emigration or 31 December 2003, whichever came first.
might contribute to the increase in cancers of estrogenresponsive tissues. It is thus biologically plausible that individuals with lack of one or two GSTT1 gene copies could be particularly susceptible to these two forms of cancer.
Cancers of estrogen-responsive tissues
In this report we provide evidence of a GSTT1 gene dosage effect on the risk of prostate cancer in men with one and zero gene copies as compared with those with two gene copies. A recent meta-analysis of GSTT1 genotype and risk of prostate cancer showed no association (odds ratio ¼ 1.05 (0.86-1.27) for the GSTT1*0/0 genotype versus the *1/0 þ *1/1 genotypes combined). 9 However, none of the 22 case-control studies in this meta-analysis discriminated between carriers of one or two functional alleles, and the results are therefore not directly comparable to ours. To our knowledge, the only study of prostate cancer risk that determined the exact copy numbers of GSTT1 was a case-control study. In this Swedish study, the GSTT1*0/0 genotype appeared to protect against prostate cancer.
26 However, considering the biological function of the GSTs mentioned above, these results are difficult to explain. Furthermore, this study is not directly comparable to ours, as ascertainment of patients with prostate cancer in Sweden differs markedly from ascertainment of patients in Denmark and other European countries. 27 Thus, large-scale well-designed studies of prostate cancer, as this study of the general population, are in high demand. 8 For corpus uteri cancer, our study is the first to report a GSTT1 gene dosage effect on risk in women with one and zero gene copies as compared with those with two gene copies. This finding is supported by previous work showing an increased risk of endometrial cancer in *0/0 versus the combined *1/0 þ *1/1 genotypes. 28 Another estrogen-responsive tissue is the female breast. We found no association between female breast cancer (n ¼ 274 cases) and GSTT1 (HRs 1.0 (0.8-1.3) for GSTT1*1/0 and 1.0 (0.7-1.5) for GSTT1*0/0 versus GSTT1*1/1; P for trend ¼ 0.93) or GSTM1 (HRs 1.6 (0.9-2.8) for GSTM1*1/0 and 1.6 (0.9-2.8) for GSTM1*0/0 versus GSTM1*1/1; P for trend ¼ 0.18). A pooled analysis including 2048 cases and 1969 controls showed no association between the null genotypes of either GSTM1 or GSTT1 and risk of breast cancer in Caucasian women. 29 However, a recent metaanalysis including 20 993 cases and 25 288 controls suggested that the GSTM1-null genotype was a low-penetrant risk factor for developing breast cancer (OR ¼ 1.10, 95% CI ¼ 1.04-1.16). 30 Another meta-analysis including 16 589 cases and 19 995 controls suggested that the GSTT1-null genotype was associated with elevated breast cancer risk (OR ¼ 1.11, 95% CI ¼ 1.04-1.20). 31 None of these metaanalyses included incident cases. Furthermore, both metaanalyses and pooled analyses a priori assumed a recessive mode of inheritance, because they included studies that discriminated only between genotypes with one or two alleles present (GST*1/0 þ GST*1/1) and genotypes with two null alleles (GST*0/0) of GSTM1 and GSTT1; they are therefore not directly comparable to our results of exact gene copy number effects. To our knowledge, the only study of breast cancer risk in Caucasians that determined exact copy numbers of GST genes, was a case-control study where the GSTM1*0/0 genotype appeared to protect against breast cancer.
32 In summary, recent meta-analyses may suggest modest increases in breast cancer risk for the null genotypes of both GSTM1 and GSTT1, whereas studies of exact GST gene copy numbers and risk of breast cancer are inconclusive.
Validation of GSTM1 CNV and bladder cancer
It is well known that GSTM1*0/0 is associated with increased risk of bladder cancer, and a recent meta-analysis showed an odds ratio of 1.5 (1.3-1.6) for the *0/0 versus the combined *1/0 þ *1/1 genotypes. 10 A gene dosage effect was reported in a large case-control study (cases, n ¼ 1,150) with risk estimates of 1.2 (0.8-1.7) for GSTM1*1/0 and 1.9 (1.4-2.7) for GSTM1*0/0.
10 This is in complete agreement with our findings where CNV in GSTM1 predicted risk of bladder cancer. Because smoking is known to predict bladder cancer, and because GSTM1 conjugates polycyclic aromatic hydrocarbons, which are particularly abundant in tobacco smoke, this association is also biologically plausible.
Five-year survival after diagnosis
Prostate cancer mortality has been associated with the GSTM1 genotype, but not GSTT1, in one study. 33 By contrast, we found CNV in GSTT1, but not in GSTM1, to be directly associated with reduced risk of all-cause mortality after prostate cancer diagnosis. The studies are not directly comparable, as we studied CNV and death of all causes, whereas Agalliu et al. studied the *0/0 versus the combined *1/0 þ *1/1 genotypes and death of prostate cancer specifically. Furthermore, we found GSTM1 gene copies to be associated with mortality after bladder cancer diagnosis. To our knowledge, no other studies have investigated this association. It is biologically plausible that cancer prognosis can be affected by detoxifying enzymes, as lack of protection against oxidative stress increases vulnerability to DNA damage and hence cancer progression. 34 Further studies are needed to elucidate the role of GST enzymes in prostate and bladder cancer prognosis.
Limitations
As we performed multiple comparisons, some of the findings could represent chance findings rather than real phenomena. We tested two CNV genes for the risk of 27 cancer subtypes and would therefore expect two to three chance findings with a significance level of P ¼ 0.05. Especially the association between genotype and brain cancer was based on very few events, was not biologically plausible and might be a chance finding.
Survival bias
This study is based on participants who survived until the 1991-1994 examination (or who were invited for the first time to this or the 2001-2003 examination) when blood samples were collected. This approach does not change the prospective nature of the study in the sense that exposure is determined before development of disease. A prerequisite for the validity of this design is that selective forces are not active against or in favor of GST*0 allele carriers. A number of observations argue against any major survival bias: (1) Genotype distributions did not differ from those predicted by the Hardy-Weinberg equilibrium, and were similar to genotype distributions reported in other Caucasian populations; (2) No excess all-cause mortality was observed in GST*1/0 and GST*0/0 individuals from 1991 to 2007 (the maximal period where mortality by GST genotypes could be examined).
Non-response
Responders and non-responders were from the same area in Copenhagen, and response rates were comparable to those observed in other epidemiological studies. 35, 36 As would be expected, standardized incidence rate for mortality per 10 000 person-years was increased in the non-responders versus that in the responders, respectively, 86 (82-90) and 45 (43-47), whereas standardized incidence rate for overall cancer was similar, respectively, 38 (35-41) and 38 (35-40) (http://www.who.int/healthinfo/paper31.pdf). The differences observed in the standardized incidence rates for mortality would not affect the estimated association between genotype and mortality, unless non-response is related to both genotype and mortality. If this was the case in this study, the GST*0 allele should be underrepresented in the responders, and the observed genotype distribution should differ from that predicted by the Hardy-Weinberg equilibrium. There were no deviations from the predicted Hardy-Weinberg equilibrium in the responders, and the GST*0 allele did not predict mortality, which argues against a strong selection bias.
Loss to follow-up
A major source of bias in cohort studies arises from loss to follow-up. 37 In the CCHS follow-up was 100% complete, that is, no participants were lost to follow-up. Loss to followup is therefore unlikely to have affected our conclusions.
Misclassification
Finally, misclassification of exposure (genotypes) or endpoint (cancer events) could have occurred. For misclassification of genotypes please refer to the section on genotyping and Nørskov et al. 11 Diagnoses of invasive cancer were obtained from the Danish Cancer Registry, which identifies 98% of all cancers in Denmark, 15 making misclassification relatively unlikely. Any misclassification of outcome in this study is likely to be random, that is, independent of exposure, and would thus tend to result in an underestimation of the true associations.
Conclusion
Exact CNV in GSTT1 and GSTM1, genes known to detoxify carcinogens, predicts incidence and 5-year survival from prostate and bladder cancer, and incidence of corpus uteri cancer in the general population in a gene-dosage-dependent manner.
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